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httpicense.Abstract The purpose of the present study was to formulate and characterize carbamazepine
loaded microemulsion and mucoadhesive microemulsion drug delivery system for its intranasal
administration. Carbamazepine microemulsion and mucoadhesive microemulsion were prepared
by titration method. The drug-loaded microemulsions were successfully prepared which contain
6% Labraﬁl M 1944 CS as an oily phase, 32% surfactant mixture of Cremophor RH 40: Transcutol
P (4:1) and 62% (wt/wt) aqueous phase. Microemulsion formulation which displayed an optical
transparency of 99.95%, globule size of 34.32 ± 1.09 nm, and polydispersity index of
0.127 ± 0.012 was selected for the incorporation of mucoadhesive component. The drug-loaded
mucoadhesive microemulsion that contains 0.5% wt/wt of polycarbophil displayed higher in vitro
mucoadhesive potential (21.0 ± 3.0 min) and diffusion coefﬁcient (0.3172 ± 0.03) than microemul-
sion. All formulations were found free from nasal ciliotoxicity and stable for 6 months.
ª 2013 Production and hosting by Elsevier B.V. on behalf of Faculty of Pharmacy, Cairo University.
Open access under CC BY-NC-ND license.1. Introduction
The treatment of brain disorders is the greatest challenge be-
cause of a variety of formidable obstacles in effective drug9824637618.
R.B. Patel).
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://dx.doi.org/10.1016/j.bfopcu.201delivery and maintaining therapeutic concentration in the
brain. General methods that can enhance drug delivery to
the brain are, therefore, of great interest. An alternative central
nervous system (CNS) drug delivery strategy that has received
relatively little attention is the intranasal route. Drugs deliv-
ered intranasally are transported along olfactory sensory neu-
rons to yield signiﬁcant concentrations in the cerebrospinal
ﬂuid (CSF) and olfactory bulb. Recent evidence of direct
nose-to-brain transport and direct access to CSF of certain
drugs bypassing the bloodstream has been shown in human
trials.1–4
Carbamazepine (CBZ) is used for the management of epi-
lepsy and several psychiatric diseases. It is traditionally givenaculty of Pharmacy, Cairo University.
3.07.002
244 R.B. Patel et al.by oral administration but due to its poor water solubility
(about 170 mg/L at 24 C) it is characterized by slow and irreg-
ular gastrointestinal absorption. Reportedly, it has an oral bio-
availability of less than 50%.5
Advantages of microemulsion (ME) include its ease of prep-
aration due to spontaneous formation, thermodynamic stabil-
ity, transparent and elegant appearance, increased drug
loading, and enhanced penetration through the biological mem-
branes, increased bioavailability and less inter- and intra-indi-
vidual variability in drug pharmacokinetics. These advantages
make ME attractive drug delivery systems.6,7 The advantages
of nasal route are rapid absorption, higher bioavailability allow-
ing lower doses, fast onset of therapeutic action, avoidance of li-
ver or gastrointestinalmetabolism, avoidance of irritation of the
gastrointestinal membrane, reduced risk of overdose, non-
invasive administration, ease of convenience and self-medica-
tion, and improved patient compliance.7,8 Targeting the brain
via nasal administration of ME has been reported in the litera-
ture.9–14
Barakat et al. designed hypromellose and Carbopol 974P
based gel formulation for intranasal administration of CBZ.
Hypromellose and Carbopol were used as mucoadhesive
polymers in the formulation to increase the residence time
of the gel on the mucosa. Results of this study revealed that
concentration of CBZ in the brain was found to be much
higher than that in the plasma following intranasal adminis-
tration; showing that there existed a direct transport pathway
from the nose to the brain and that transport was compara-
tively rapid.5 Gavin et al. prepared chitosan glutamate based
microspheres for the nasal administration of CBZ. The re-
sults obtained indicate that the loading of CBZ in chitosan
glutamate microspheres increases the amount of the drug ab-
sorbed through the nose.15 However, few formulation factors
need to be addressed while designing the drug delivery system
for the intranasal administration. A lipophilic component in
the formulation seems to be advantageous, but in the case
of nasal administration, incompatibilities can be indicated
by impairment of ciliary movement. Use of ME may mini-
mize these side effects by administering a lipophilic compo-
nent in a transparent, water-continuous, less viscous system.
Nasal mucociliary clearance is one of the most important lim-
iting factors for nasal drug delivery. However, mucoadhesive
preparations have been developed to increase the contact
time between the dosage form and mucosal layers of nasal
cavities, thus enhancing drug absorption and preventing ra-
pid nasal clearance. This study aims at using polycarbophil
as a mucoadhesive component in designing mucoadhesive
microemulsion (MME).
Although IV administration is probably the most rapid
way of seizure suppression, an alternative and more conve-
nient approach like MME is highly needed when IV admin-
istration is not immediately available, for instance, because
of the delay in transferring the patient to hospital or the ar-
rival of emergency medical personnel. This study aimed to
develop and characterize new ME and MME formula for
intranasal delivery of CBZ and it was hypothesized that it
will be able to reduce the side effects, decrease the dose
and frequency of administration, and perhaps even the cost
of the therapy.2. Experimental
2.1. Drugs and reagents
Pure powdered CBZ was obtained as gratis sample from Max
Pharma (India) with 99.9% purity. Labraﬁl M 1944 (Oleoyl
polyoxylglycerides), Transcutol P (Diethylene glycol monoeth-
yl ether), Labrafac CC (Gattefosse Saint-Priest, France) was
procured as gratis sample from Gattefosse Asia Ltd. (Mumbai,
India). Cremophor RH 40 (Polyoxyl 40 Hydrogenated Castor
Oil) was procured as gratis sample form BASF (Mumbai, In-
dia). Polycarbophil (AA-1, pharmagrade, molecular weight
approximately 3.5 million) was procured as gratis sample from
Lubrizol Advance Material India Pvt. Ltd. (Mumbai, India).
Potassium dihydrogen phosphate, methanol, propylene glycol
were purchased from SDﬁne Chemicals (Ahmedabad, India).
Ethanol was purchased from Baroda Chemical Ind. Ltd. (Dab-
hoi, India). Double distilled water was used throughout the
study. All other chemicals and solvents were of analytical re-
agent grade and used as received without further puriﬁcation.
2.2. High performance thin layer chromatography method and
chromatographic conditions
The standard and formulation samples of CBZ were spotted
on pre-coated high performance thin layer chromatogra-
phy(HPTLC) plates in the form of narrow bands of lengths
6 mm, with 10 mm from the bottom and left margin and with
9 mm distance between two bands. Samples were applied using
Linomat V autosprayer under continuous drying stream of
nitrogen gas at a constant application rate of 150 nL/s. Plates
were developed using a mobile phase consisting of ethyl ace-
tate–toluene–methanol (5.0 + 4.0 + 1.0 v/v/v). Linear ascend-
ing development was carried out in 10 cm · 10 cm twin trough
glass chamber equilibrated with the mobile phase. The opti-
mized chamber saturation time for mobile phase was 20 min
at 25 ± 2 C. Ten milliliters of the mobile phase (5 mL in
trough containing the plate and 5 mL in other trough) was
used for each development and allowed to migrate a distance
of 70 mm, which required 10 min. After development, the
HPTLC plates were dried completely. Densitometric scanning
was performed on Camag TLC scanner III (Camag, Muttenz,
Switzerland) in absorbance mode and operated by winCATS
planar chromatography version 1.3.4. The source of radiation
utilized was a deuterium lamp. The spots were analyzed at a
wavelength of 285 nm. The slit dimensions used in the analysis
were length and width of 5 mm and 0.45 mm, respectively,
with a scanning rate of 20 mm/s. These are selected as recom-
mended by the CAMAG TLC Scanner III manual. It covers
70–90% of the application band length, which in the present
case is 6 mm. The monochromator bandwidth was set at
20 nm. Concentrations of compound chromatographed were
determined from the intensity of diffusely reﬂected light and
evaluated as peak areas against concentrations using linear
regression equation. The method was validated for precision,
recovery, repeatability, and robustness as per the International
Conference on Harmonization guidelines.16 Fig. 1 shows a
typical chromatogram obtained by the proposed HPTLC
Figure 1 Chromatogram of standard solution containing
400 ng/spot Carbamazepine.
Table 1 Composition of carbamazepine microemulsions
(CME) and carbamazepine mucoadhesive microemulsions
(CMME).
Ingredients CMEa (% wt/wt) CMMEa (% wt/wt)
Labraﬁl M 1944 6.00 6.00
Cremophor RH 40 8.00 8.00
Transcutol P (4:1) 24.00 24.00
Water 62.00 62.00
* The formulations contain carbamazepine 5 mg/mL; CMME
additionally contain 0.5% wt/wt of polycarbophil as mucoadhesive
agent.
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CBZ.
2.3. Solubility determination
Drug powder of CBZ was added in excess to each of the oils,
surfactant (S) and cosurfactant (CoS) and vortexed for mixing.
After vortexing the samples were kept for 72 h at ambient tem-
perature for attaining equilibrium. The equilibrated samples
were then centrifuged at 5000 rpm for 30 min to remove the
undissolved drug.6 The aliquots of supernatant were ﬁltered
through 0.45 m membrane ﬁlters and the solubility of CBZ
was determined by HPTLC16 method.
2.4. Pseudo-ternary phase diagram
In order to ﬁnd out the concentration range of components for
the existing range of ME, pseudo-ternary phase diagrams were
constructed using water titration method6 at ambient temper-
ature. Four phase diagrams were prepared with the 1:1, 2:1, 3:1
and 4:1 weight ratios of Cremophor RH 40 to Transcutol P,
respectively. For each phase diagram at a speciﬁc S/CoS mix-
ing ratio (km), the ratios of oil to the mixture of S/CoS (Smix)
were varied as 0.5:9.5, 1:9, 1.5:8.5, 2:8, 2.5:7.5, 3:7, 3.5:6.5, 4:6,
4.5:5.5, 5:5, 5.5:4.5, 6:4, 6.5:3.5, 7:3, 7.5:2.5, 8:2, 8.5:1.5, 9:1,
9.5:0.5. The mixtures of oil and S/CoS at certain weight ratios
were diluted with water dropwise, under moderate magnetic
stirring. After being equilibrated at ambient temperature for
24 h, the mixtures were assessed visually and determined as
being ME, crude emulsions or ME gels. The stable ME formu-
lations were also observed under polarizing light to conﬁrm
their isotropic nature. No attempt was made to distinguish be-
tween oil-in-water, water-in-oil or bicontinuous type ME. Gels
were claimed for those clear and highly viscous mixtures that
did not show a change in the meniscus after being tilted to
an angle of 90.2.5. Optimization of microemulsions
Considering the amount and solubility of drug to be incorpo-
rated in the ME, certain Oil–Smix–water mixture within the
ME region was prepared and the ﬁnal composition of ME
was optimized based on transparency, dilution characteristics,
and globule size. For optimization process, the ME formula-
tions were prepared by varying the stirring speed and stirring
time and the globule size was taken as response.
2.6. Preparation of microemulsions and mucoadhesive
microemulsions
The ME for CBZ was prepared by the titration method. The
calculated amount of drug (5 mg/mL of CBZ) was added to
the oily phase of ME and magnetically stirred until dissolved
followed by the addition of Smix in a ﬁxed proportion to pro-
duce a clear mixture. Then a deﬁned proportion of water was
added and stirred to produce clear ME of CBZ (CME). The
MME of CBZ (CMME) was prepared by initially preparing
ME of the drug using a a minimum volume of external phase
and then adding the required volume of polymer solution (1%,
wt/vol) so that the ﬁnal concentration of polymer in the MME
was 0.5% (wt/wt). After the addition of polymer solution the
MME was allowed to homogenize for 10 min. Composition
of CME and CMME is shown in Table 1.
2.7. Preparation of drug solution
The CBZ solution (CS) meant for comparative evaluation of
MME-based systems was prepared by dissolving CBZ
(50 mg) in a mixture of 5 mL propylene glycol, 3 mL water
and 2 mL ethanol (95%, vol/vol) resulting in a solution of
5 mg/mL.
2.8. Physicochemical characterization of MEs
2.8.1. Particle size and zeta potential measurements
The average droplet size and polydispersity index (PDI) of ME
were measured by photon correlation spectroscopy (PCS) with
an in-built Zetasizer (Nano ZS, Malvern Instruments, UK) at
633 nm. Helium–neon gas laser having intensity of 4 mW was
the light source. The droplet size was calculated using the
Stokes–Einstein relationship by Zetasizer Software. Electro-
phoretic mobility (lm/s) was measured using small volume dis-
posable zeta cell and converted to zeta potential17 by in-built
246 R.B. Patel et al.software using the Helmholtz–Smoluchowski equation. All
determinations were made in triplicate.
2.8.2. Transmission electron microscopy (TEM)
TEM was used to characterize the microstructure of CBZ
loaded ME. CME was placed on a carbon-coated copper grid
and then a drop of 1% phosphotungstic acid was covered on
ME. The superﬂuous phosphotungstic acid on ME was wiped
off by ﬁlter paper. The TEM images were obtained using a
Tecnai G2 20 TEM (Philips, Holland).
2.8.3. Refractive index and percent transmittance measurement
The refractive index of the system was measured by a digital
Abbe refractometer (Atago Co. Ltd., Tokyo, Japan) by plac-
ing 1 drop of ME on the slide. The percent transmittance of
the system was measured using a colorimeter (Digital Colorim-
eter, D-801, Photocon) at 570–590 nm.
2.8.4. Polarizing microscopy
In order to verify the isotropic nature of ME, samples were
examined using cross-polarized light microscopy (Polarizing
Microscope RPL-55 Series, Radical Instruments, India). A
drop of ME was placed between a cover slip and a glass slide
and then observed under cross-polarized light.6
2.8.5. pH measurement
The pH value of ME was determined using digital pH meter
(Orion pH meter 420A, Allometric Ltd., Baton Rouge, LA),
standardized using pH 4 and 7 buffers before use.
2.8.6. Osmolarity determination
The osmolarity of the formulations was determined by the fol-
lowing expression, 18
mOsm=liter ¼ðconcentration in gram per liter=
molecular weight in gramsÞ  10; 000: ð1Þ2.8.7. Viscosity measurement
The viscosity of ME was measured using a Brookﬁeld Viscom-
eter LVDV – IIIU (Brookﬁeld Engineering LABS, Stoughton,
MA) with spindle SC 18 at 100 rpm using interval of 30 s. All
aspects of testing were controlled using Rheocalc Software.6
2.8.8. Conductivity measurement
The electrical conductivity of ME was measured with a con-
ductivity meter (Equip-Tronics, EQ – 664, Mumbai, India)
equipped with an inbuilt magnetic stirrer. This was done by
using conductivity cell (with a cell constant of 1.0) consisting
of two platinum plates separated by desired distance and hav-
ing liquid between the platinum plate acting as a conductor.6
All determinations were made in triplicate.
2.8.9. Infrared study
The infrared (IR) spectra of CBZ, plain ME, optimized CME
and CMME were taken using an IR spectrophotometer (Spec-
trum GX FT-IR, Perkin Elmer, Norwalk, CT). The plain ME,
CME and CMME were spread as a thin layer onto a potas-
sium bromide cell and then scanned between 4000 and
400 cm1. The resulting IR spectra of CBZ and plain ME werethen compared with CME and CMME to detect any possible
interaction between the drug and different components used.
2.9. Ex vivo evaluation of carbamazepine formulations
2.9.1. Ex vivo diffusion study of carbamazepine formulations
The freshly excised sheep nasal mucosa,19 except the septum
part, was collected from the slaughter house in phosphate buf-
fer saline (PBS), pH 6.4. The membrane was kept in PBS at pH
6.4 for 15 min to equilibrate. The superior nasal concha was
identiﬁed and separated from the nasal membrane. The excised
superior nasal membrane was then mounted on a Franz diffu-
sion cell. The tissue was stabilized using phosphate buffer pH
6.0 in both the compartments and allowed to stir for 15 min on
a magnetic stirrer. After 15 min, solution from both the com-
partments was removed and fresh phosphate buffer pH. 6.05
was ﬁlled in the receptor compartment. The mounting of the
nasal membrane was done using glue at the brim of the donor
compartment to avoid leakage of the test sample and sup-
ported with thread crossing over the cell.
Franz diffusion cell used for ex vivo diffusion studies had a
diameter of 10 mm and mucosa of thickness 0.2 ± 0.1 mm.
The temperature of the receiver chamber containing 25 mL
of diffusion media (phosphate buffer, pH 6.0) was controlled
at 37 C± 1 using circulating equibath, (Model 8506, Medica
Instrument Mfg. CO, Mumbai, India). Diffusion media was
continuously stirred with a Teﬂon-coated magnetic bar at a
constant rate, in a way that the nasal membrane surface just
ﬂushes the diffusion ﬂuid.
A volume of 1 mL of each CS, CME, and CMME was
placed in the donor compartment of Franz diffusion cell. Sam-
ples from the receptor compartment were withdrawn at prede-
termined time intervals and analyzed using the HPTLC
method. Each sample removed was replaced by an equal vol-
ume of diffusion media (1 mL). Each study was carried out
for a period of 4.0 h, during which the drug in the receiver
chamber (lg/mL) across the sheep nasal membrane was calcu-
lated at each sampling point. The formulations were studied in
triplicate for diffusion studies and the mean cumulative values
for % of drug diffused were plotted against time. The slopes of
the graphs were used to calculate the diffusion coefﬁcients and
the results were subjected to one-way ANOVA.
2.9.2. Test for nasal cilio toxicity of microemulsion
Freshly excised sheep nasal mucosa, except for the septum,
was collected from the slaughter house in saline phosphate
buffer pH 6.4. Three sheep nasal mucosa pieces (S1, S2, and
S3) with uniform thickness were selected and mounted on
Franz diffusion cells. S1 was treated with 0.5 mL of PBS pH
6.4 (negative control), S2 with 0.5 mL of isopropyl alcohol
(positive control), and S3 was treated with ME for 1 h. After
1 h, the mucosae were rinsed with PBS at pH 6.4 and subjected
to histological studies to evaluate the toxicities of ME photo-
graphed by microscope.
2.9.3. Ex vivo mucoadhesion study
The mucoadhesive potential of the CME and CMME was
evaluated by an in vitro method reported by Bachhav and Pat-
ravale.20 Brieﬂy, an agar plate (1%, w/w) was prepared in pH
6.0 phosphate buffer, CME and CMME formulations, each
Formulation consideration and characterization of microemulsion drug delivery system 24750 mg was placed at the center of plate. After 5 min, the agar
plate was attached to a USP disintegration test apparatus and
moved up and down in pH 6.0 phosphate buffer at 37 ± 1 C.
The CMME formulation on the plate was immersed into the
solution at the lowest point and was out of the solution at
the highest point. The residence time of the CMME on the
plate was noted visually.
2.10. Stability studies
The formulations, CME and CMME, were subjected to stabil-
ity testing for a period of 6 months at room temperature to
simulate patient usage conditions. After 6 months of storage,
the formulations were studied for physical stability by means
of creaming, phase separation, or ﬂocculation, accelerated cen-
trifugation cycle (3000·g for 15 min) and chemical stability by
means of drug content, particle size, and zeta potential
determinations.173. Results and discussion
3.1. Preparation and optimization of microemulsion
formulations
The solubility of practically insoluble CBZ was determined in
the selected oily phases and was highest in Labraﬁl M 1944 CS
(Table 2). Hence, Labraﬁl M 1944 CS was selected as the oily
phase for the preparation of ME. The type of ME formedTable 2 Solubility of carbamazepine in vari
Excipients
Oily phases
Labraﬁl M 1944 (oleoyl polyoxylglycerides)
Labrafac CC (caprylic/capric triglycerides)
Isopropyl myristate
Labrafac lipophile (medium chain triglycerides)
Labrafac PG (propylene glycol dicaprylocaprate
Miglyol 810 (Caprylic/Capric Triglyceride)
Miglyol 812 (Caprylic/Capric triglyceride)
Miglyol 840 (propylene glycol dicaprylate/dicap
Lauryl alcohol
Isostearylic isostearate
Isopropyl palmitate
Captex 200 (propylene glycol dicaprylate/dicapr
Captex 355 (glycerol caprylate caprate)
Surfactants
Labrasol (caprylocaproyl polyoxylglycerides)
Tween (polysorbate) 80
Plurol stearique WL (polyglyceryl-6-distearate)
Plurol diisostearique (Polyglyceryl diisostearate)
Cremophor RH 40 (polyoxyl 40 hydrogenated c
Cosurfactants
Plurol Oleique CC (polyglyceryl oleate)
Plurol oleique 5203 (Polyglyceryl 6 – dioleate)
Lauroglycol 90 (propylene glycol monolaurate)
Capryol 90 (Propylene glycol monocaprylate)
Transcutol P (diethylene glycol monoethyl ether
Capmul MCM (glyceryl mono- and dicaprate)
Propylene glycol
a Data expressed as mg/g, mean ± SD, n = 3depends on the properties of the oil, S, and CoS. Most
single-chain S does not lower the oil–water interfacial tension
sufﬁciently to form ME and short-to-medium-chain length
alcohols are necessary as CoS. The CoS also ensures that the
interfacial ﬁlm is ﬂexible enough to deform readily around
each droplet as their intercalation between the primary S mol-
ecules decreases both the polar head group interactions. In this
study, cremophor RH 40 and transcutol P were selected as the
S–CoS system. An important criterion for selection of the sur-
factants is that the required hydrophilic lipophilic balance
(HLB) value to form the oil–water ME be greater than 10.
The right blend of low and high HLB S leads to the formation
of a stable ME formulation.21 In this study, we selected
cremophor RH 40 as S with a HLB value of 15. Transient
negative interfacial tension and ﬂuid interfacial ﬁlm are rarely
achieved by the use of single surfactant; usually, addition of a
CoS is necessary. The presence of CoS decreases the bending
stress of interface and allows the interfacial ﬁlm with sufﬁcient
ﬂexibility to take up different curvatures required to form
ME over a wide range of compositions.22 Thus, the CoS se-
lected for the study was transcutol P, which has an HLB value
of 4.2.
A ternary phase diagram explains the selection of the for-
mulations from the phase diagrams to avoid metastable for-
mulations having minimum surfactant concentration, in the
least possible time. Ternary phase diagrams were constructed
by varying cremophor RH 40: transcutol P ratios as 1:1, 2:1,
3:1, and 4:1 (Fig. 2). The shaded areas of phase diagrams show
the ME regions, whereas the nonshaded area displays theous excipients.
Solubilitya
37.7 ± 4.21
10.47 ± 3.6
21.9 ± 3.9
0.9 ± 0.7
) 1.1 ± 0.7
1.31 ± 1.0
1.6 ± 0.9
rate) 0.7 ± 0.36
1.8 ± 0.6
1.44 ± 0.6
0.35 ± 0.21
ate) 3.8 ± 0.9
1.8 ± 0.7
165.8 ± 6.16
75.0 ± 6.18
0.8 ± 0.15
1.05 ± 0.7
astor oil) 25.34 ± 6.11
4.13 ± 1.1
1.7 ± 0.8
49.8 ± 3.1
87.44 ± 5.8
) 157.23 ± 7.34
11.14 ± 4.1
150.9 ± 4.6
.
Figure 2 The pseudoternary phase diagrams of the oil-surfactant mixture-water system at the 1:1, 2:1, 3:1 and 4:1 weight ratio of
Cremophor RH 40 to Transcutol P at ambient temperature, dark area represent microemulsion region.
Table 3 Various ternary phase compositions and characterization parameters of plain microemulsions.
Batch Km Oil (% wt/wt) Smix (%wt/wt) Water (%wt/wt) Globule Size (nm) ± SD PDI ± SD Zeta potential (mV) ± SD % T
L1
4 6 22 72 139.0 ± 4.17 0.226 ± 0.021 19.12 ± 2.79 96.35
L2
4 6 24 70 113.0 ± 2.88 0.442 ± 0.016 11.34 ± 2.74 97.12
L3
4 6 26 68 107.0 ± 2.63 0.332 ± 0.027 16.45 ± 2.46 99.78
L4
4 6 28 66 67.0 ± 1.28 0.122 ± 0.010 25.09 ± 1.88 99.23
L5
4 6 30 64 45.0 ± 1.44 0.136 ± 0.014 24.72 ± 2.25 99.61
L6
4 6 32 62 34.32 ± 1.09 0.116 ± 0.012 36.29 ± 2.03 99.95
L7
4 6 34 60 34.16 ± 1.36 0.127 ± 0.023 36.79 ± 2.66 99.87
L8
4 6 36 58 32.53 ± 1.78 0.129 ± 0.038 36.52 ± 2.18 99.69
248 R.B. Patel et al.turbid region. Thus, the ternary phase system of Smix (4:1, Km
4) that exhibited maximum area for ME formation was se-
lected for the optimization of ME batches. Apart from the ter-
nary phase diagrams, globule size determinations were also
performed as it could provide supportive evidence for the
selection of phase diagram of ratio 4:1. It was clearly evident
that an increase in the concentration of Cremophor RH 40 re-sulted in a decrease in globule size. Thus, at the lowest concen-
tration of S, the globule size was 68.31 ± 2.27 nm, whereas at
the highest concentration of Cremophor RH 40 it reduced to
30.32 ± 1.09 nm, and hence the ratio of Smix 4:1 (Km 4)
was selected for optimization studies. The optimization of
ME was carried out on the basis of percentage transmittance
(%T), globule size, and zeta potential, and the results are
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in Labraﬁl M 1944 CS, a minimum of 6% by the weight of oily
phase was required to fulﬁll the dose requirement, and with
Smix maintained at 4:1 and water at 62% by weight, eight
batches of CBZ-loaded ME formulations were prepared and
characterized.
The globule size decreased with the increase in the concen-
tration of Smix in the formulations (Table 3). The globule size
of batch L1, containing 22% of Smix, was highest
(139.0 ± 4.17 nm) and was least (32.53 ± 1.78 nm) for highest
concentration (36%) of the Smix. All the formulations had
droplets in the nano range, which is very well evident from
the low PDI values. PDI is the ratio of standard deviation to
mean droplet size; hence, it indicates the uniformity of droplet
size within the formulation. The higher the PDI, the lower the
uniformity of the droplet size in the formulation.6 Although
the PDI values of all formulations were very low, indicating
uniformity of droplet size within each formulation, it was least
for L6 (0.116 ± 0.012).
The batch L6 (oil: S–CoS: water, 6:32:62) was selected as the
optimized batch as it displayed optimum response variables
of 99.95% optical transparency, low globule size
(34.32 ± 1.09 nm), polydispersity of 0.116 ± 0.012, and zeta
potential to the tune of 36.29 ± 3.03. Although batches L7
and L8 showed lower values for globule size and PDI that
may be attributed to higher Smix concentrations, the difference
was insigniﬁcant (p< .05) when compared with L6. Moreover,
higher concentrations of Smix may cause damage to nasal
mucosa; hence, L6 was selected for further processing.
The process for the preparation of ME was optimized by
varying the stirring speed (200, 500, and 800 rpm) and time (5,
10, and 20 min for each stirring speed) followed by the globule
size determination. Based on the minimum globule size of
32.53 ± 1.78 nm, a stirring speed of 800 rpm and stirring time
of 10 min were selected as the optimized process parameters
to obtain drug-loaded ME. ME form spontaneously without
the aid of high shear equipment or signiﬁcant heat input (heat
and gentle mixing are required only if it is necessary to melt
any of the ingredients), and their microstructures are indepen-
dent of the order of addition of the excipients.
3.2. Characterization of microemulsion
Characterization data of CME are tabulated in Table 4. The
narrow globule size range of 34–41 nm and PDI of 0.127 and
0.134 for CME and CMME, respectively, indicated that the
ME approached a monodispersed stable system and could de-
liver the drug effectively owing to larger surface area. The
globule size of the batch L6 containing carbamazepine was
not signiﬁcantly affected by incorporation of the drug when
compared to the globule size of ME prepared without drug.
The presence of zeta potential to the tune of –36.29 and –
48.58 mV on the globules of CME, and CMME, respectively,
conferred physical stability to the system. CME showed net
negative charge and addition of mucoadhesive agent further
contributed negatively to the system. This may be attributed
to the fact that the increase in surfactant level resulted in a
decrease in surface tension and surface free energy of the
formed micelles. Therefore, net negative charge (anionic) of
the ME increased.10 The microemulsions were expected to
have good physical stability (phase separation) as zeta
potential is less than 30 mV.11 Moreover, addition of a
Table 5 Diffusion coefﬁcients and modeling parameters of
CBZ solution (CS), CBZ microemulsions (CME) and CBZ
mucoadhesive microemulsions (CMME).
Formulation Diﬀusion
coeﬃcient
(cm2/min)
Zero order First order Higuchi
r2 r2 r2
CS 0.3421 ± 0.08 0.8735 0.8988 0.9355
CME 0.2913 ± 0.11 0.9067 0.9013 0.9745
CMME 0.3172 ± 0.03 0.9128 0.9527 0.9873
Figure 4 Infra Red spectra of (A) Carbamazepine (CBZ), (B)
plain microemulsion (ME) (C) Drug loaded microemulsion (CME)
and (D) drug loaded mucoadhesive microemulsion (CMME).
Figure 5 Percentage cumulative drug diffused versus time
proﬁles of Carbamazepine solution (CS), microoemulsion
(CME), and mucoadhesive microemulsions (CMME).
Figure 3 Transmission electron microscopy image of carbam-
azepine loaded microemulsion.
250 R.B. Patel et al.mucoadhesive polymer (Polycarbophil) may further stabilize
the system since it increased the negative charge of the
system.12
The TEM imaging of CME is shown in Fig. 3. The globule
size of CME from TEM images accords with that from PCS.
The imaging showed that CME exhibited a spherical shape
and had a narrow size distribution.
The refractive index values of the developed ME formula-
tion, CME and CMME were found to be 1.3902 and 1.4021,
respectively. A percentage transmittance of 99.95 for CME
indicated clear dispersion, whereas CMME, no transmittance
was hazy due to the presence of mucoadhesive component in
the formulations.
The samples were examined by ocular inspection in a cross
polarizer for sample homogeneity and birefringence. The ME
appeared completely dark when observed under a cross pola-
rizer. The observations indicated that all the ME formulations
were optically isotropic colloidal dispersions.
The pH of all the ME ranged between 4.5 and 6.5, approx-
imating the normal pH range of nasal ﬂuids,4 which is one of
the formulation considerations that may help reducing the irri-
tation produced upon instillation.
Although the nasal passages can tolerate a wide range of
tonicity without pain, isotonicity is signiﬁcantly important. Na-
sal solutions with osmolarity comparable to aqueous 0.5–2.0%
(equivalent to 85.47–341.88 mOsmol/L) sodium chloride solu-
tion are relatively comfortable and do not harm nasal cilia. Cal-
culated osmolarity for both CME and CMME formulations
was 211.62 mOsmol/L, which is within the suggested limits
and the preparations are unlikely to cause potential discomfort
upon instillation. All the formulations were of an osmolarity of
almost similar magnitude as the presence of high molecular
weight (300,000)mucoadhesive agents (0.5%byweight of pol-
ycarbophil) contributed negligibly to the osmolarity.
It was observed that the viscosity of the ME formulations
generally was very low. This was expected, because one of
the characteristics of ME formulations is of a lower viscosity.23
Low viscosity values of CME and CMME were 186 ± 4.63
and 201 ± 6.82 cp respectively, ensure easy handling, packing,
and hassle-free nasal administration of formulations.
Conductivity measurements rely on the poor conductivity
of oil compared with water and give low values for water in
oil ME where oil is the continuous phase. The reverse happens
for oil in water ME.7 The conductivity measurements (0.169–
0.103 mS) indicate the ME to be of oil-in-water type.The infrared spectra of CBZ pure powder, plain ME, CME
and CMME are as shown in the Fig. 4. The spectrum of CBZ
shows two principle absorption bands, one absorption band at
3460 cm1 due to –NH valence vibration and other at
Figure 6 Photographs of sheep nasal mucosa demonstrating histological characteristics when treated with (A) phosphate buffer saline
pH 6.4 (B) isopropyl alcohol and (C) mucoadhesive microemulsion of carbamazepine.
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fected by components of formulation present in ME and
MME, which emphasized the absence of any possible
interaction between the drug and formulation components
used.
3.3. Ex vivo diffusion study
In ex vivo diffusion studies of CBZ formulations, the recorded
successful diffusion through sheep nasal mucosa and the re-
sults obtained are presented in Fig. 5, and the calculated
diffusion coefﬁcients are tabulated in Table 5 along with the
regression coefﬁcients (r2) for ﬁrst-order, Higuchi, and zero-
order modeling of the diffusion proﬁles for each formulation.
The decreasing order of diffusion coefﬁcient for the tested
formulations was CME< CMME< CS (although not signif-
icantly different at p< .05). For CS, the drug exhibited the
highest diffusion coefﬁcient, whereas it was least for CNE.
The CMME exhibited a higher diffusion due to the presence
of mucoadhesive agent that probably due to its intrinsic char-
acter tends to adhere to the mucosa thereby causing increased
contact and hence increased diffusion.24–26On modeling, the diffusion of drug from CBZ formulations
exhibited higher r2 values for the Higuchi model compared
with zero- and ﬁrst-order model(s). This may be due to the fact
that the diffusion system used has a reservoir compartment
(donor compartment) and sheep mucosa acts as a barrier or
controlling membrane; hence, the diffusion process will mimic
and shall be closer to the reservoir system than zero-order
(concentration independent) or ﬁrst-order (concentration gra-
dient) diffusion.25–27
3.4. Nasal ciliotoxicity study
Nasal cilio-toxicity studies were carried out in an attempt to
evaluate any potential toxic effects of excipients used in the
formulation on the nasal mucosa. The nasal mucosa treated
with PBS (pH 6.4, negative control) showed no nasociliary
damage (Fig. 6A) and the nasal membrane remained intact,
whereas an extensive damage to nasal mucosa coupled with
loss of nasal cilia (Fig. 6B) could be observed with positive
control. However, with ME, no damage to nasal mucosa could
be observed (Fig. 6C), thus substantiating the safety of the
excipients used in the formulation.
Table 6 Results of stability testing of the cbz microemulsions
(CME) and CBZ mucoadhesive microemulsions containing
0.5% (wt/wt) polycarbophil (CMME) at room temperature.
Test CME CMME
% Assay 98.43 99.72
% Transmittance 99.80 97.56
Globule size (nm) 36.48 44.32
Polydispersibility index 0.143 0.159
Zeta potential (mV) 37.24 49.37
252 R.B. Patel et al.3.5. In vitro mucoadhesion study
The mucoadhesive potential of CMME was evaluated by
in vitro method. The retention times showed by CME and
CMME were 5.0 ± 1.0 and 21.0 ± 3.0 min, respectively
(n = 3). The retention time on agar plate showed by CMME
was signiﬁcantly higher than CME. Thus it was hypothesized
that the developed mucoadhesive preparation, CMME able
to increase the contact time between the dosage form and
mucosal layers of nasal cavities which can be attributed due
to the presence of polycarbophil (0.5% wt/wt).
3.6. Stability study
In stability studies, the ME exhibited no precipitation of drug,
creaming, phase separation, and ﬂocculation on visual
observation and was found to be stable after centrifugation
(3000·g for 15 min) at room temperature. The results of stabil-
ity studies (Table 6) showed that there are negligible changes in
the parameters of CME and CMME after 3 months of storage,
thus substantiating the stability of ME for 3 months.
4. Conclusion
On the basis of low droplet size and PDI, optimum S and CoS
concentrations, the mucoadhesive formulation CMME of
CBZ that contained 0.5% by weight of polycarbophil as the
mucoadhesive component displayed highest diffusion coefﬁ-
cient. The formulation was free from nasal ciliotoxicity and
was found to be stable for 3 months. The Ex vivo studies dem-
onstrated the potential of developed CMME for intranasal
delivery of CBZ.
Further in vivo studies are necessary to demonstrate the po-
tential of MME based drug delivery system and to conﬁrm the
existence of a transport pathway for a drug (CBZ) to the brain
directly from the nasal cavity. Thus authors are currently
working on the brain targeting study of technetium-labeled
CMME formulation in rabbit.
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